nodes	percent_of_prediction	percent_of_DWPC	metapath
Tapentadol—CYP2C9—Estropipate—osteoporosis	0.105	0.284	CbGbCtD
Tapentadol—CYP2C19—Cholecalciferol—osteoporosis	0.065	0.176	CbGbCtD
Tapentadol—CYP2C9—Cholecalciferol—osteoporosis	0.0541	0.146	CbGbCtD
Tapentadol—CYP2C19—Estradiol—osteoporosis	0.0524	0.142	CbGbCtD
Tapentadol—CYP2D6—Cholecalciferol—osteoporosis	0.0495	0.134	CbGbCtD
Tapentadol—CYP2C9—Estradiol—osteoporosis	0.0436	0.118	CbGbCtD
Tapentadol—Urticaria—Calcitriol—osteoporosis	0.000747	0.0013	CcSEcCtD
Tapentadol—Palpitations—Zoledronate—osteoporosis	0.000744	0.0013	CcSEcCtD
Tapentadol—Hypoaesthesia—Estradiol—osteoporosis	0.000741	0.00129	CcSEcCtD
Tapentadol—Angioedema—Conjugated Estrogens—osteoporosis	0.000741	0.00129	CcSEcCtD
Tapentadol—Shock—Pamidronate—osteoporosis	0.00074	0.00129	CcSEcCtD
Tapentadol—Loss of consciousness—Zoledronate—osteoporosis	0.00074	0.00129	CcSEcCtD
Tapentadol—Hypersensitivity—Estropipate—osteoporosis	0.000738	0.00129	CcSEcCtD
Tapentadol—Nervous system disorder—Pamidronate—osteoporosis	0.000738	0.00129	CcSEcCtD
Tapentadol—Urinary tract disorder—Estradiol—osteoporosis	0.000736	0.00128	CcSEcCtD
Tapentadol—Vomiting—Etidronic acid—osteoporosis	0.000736	0.00128	CcSEcCtD
Tapentadol—Cough—Zoledronate—osteoporosis	0.000734	0.00128	CcSEcCtD
Tapentadol—Tachycardia—Pamidronate—osteoporosis	0.000734	0.00128	CcSEcCtD
Tapentadol—Connective tissue disorder—Estradiol—osteoporosis	0.000732	0.00128	CcSEcCtD
Tapentadol—Urethral disorder—Estradiol—osteoporosis	0.00073	0.00127	CcSEcCtD
Tapentadol—Rash—Etidronic acid—osteoporosis	0.00073	0.00127	CcSEcCtD
Tapentadol—Convulsion—Zoledronate—osteoporosis	0.000729	0.00127	CcSEcCtD
Tapentadol—Dermatitis—Etidronic acid—osteoporosis	0.000729	0.00127	CcSEcCtD
Tapentadol—Vertigo—Conjugated Estrogens—osteoporosis	0.000728	0.00127	CcSEcCtD
Tapentadol—Hyperhidrosis—Pamidronate—osteoporosis	0.000727	0.00127	CcSEcCtD
Tapentadol—Syncope—Conjugated Estrogens—osteoporosis	0.000727	0.00127	CcSEcCtD
Tapentadol—Hypersensitivity—Alendronate—osteoporosis	0.000726	0.00127	CcSEcCtD
Tapentadol—Headache—Etidronic acid—osteoporosis	0.000725	0.00126	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Risedronate—osteoporosis	0.000721	0.00126	CcSEcCtD
Tapentadol—Asthenia—Estropipate—osteoporosis	0.000718	0.00125	CcSEcCtD
Tapentadol—Visual impairment—Estradiol—osteoporosis	0.000718	0.00125	CcSEcCtD
Tapentadol—Arthralgia—Zoledronate—osteoporosis	0.000717	0.00125	CcSEcCtD
Tapentadol—Palpitations—Conjugated Estrogens—osteoporosis	0.000716	0.00125	CcSEcCtD
Tapentadol—Insomnia—Risedronate—osteoporosis	0.000716	0.00125	CcSEcCtD
Tapentadol—Anxiety—Zoledronate—osteoporosis	0.000714	0.00125	CcSEcCtD
Tapentadol—Loss of consciousness—Conjugated Estrogens—osteoporosis	0.000712	0.00124	CcSEcCtD
Tapentadol—Unspecified disorder of skin and subcutaneous tissue—Zoledronate—osteoporosis	0.000712	0.00124	CcSEcCtD
Tapentadol—Paraesthesia—Risedronate—osteoporosis	0.00071	0.00124	CcSEcCtD
Tapentadol—Pruritus—Estropipate—osteoporosis	0.000708	0.00124	CcSEcCtD
Tapentadol—Asthenia—Alendronate—osteoporosis	0.000707	0.00123	CcSEcCtD
Tapentadol—Hypersensitivity—Ibandronate—osteoporosis	0.000707	0.00123	CcSEcCtD
Tapentadol—Cough—Conjugated Estrogens—osteoporosis	0.000707	0.00123	CcSEcCtD
Tapentadol—Dyspnoea—Risedronate—osteoporosis	0.000705	0.00123	CcSEcCtD
Tapentadol—Hypotension—Pamidronate—osteoporosis	0.000703	0.00123	CcSEcCtD
Tapentadol—Convulsion—Conjugated Estrogens—osteoporosis	0.000702	0.00123	CcSEcCtD
Tapentadol—Dry mouth—Zoledronate—osteoporosis	0.000701	0.00122	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Ethinyl Estradiol—osteoporosis	0.000701	0.00122	CcSEcCtD
Tapentadol—Fatigue—Ethinyl Estradiol—osteoporosis	0.0007	0.00122	CcSEcCtD
Tapentadol—Pruritus—Alendronate—osteoporosis	0.000698	0.00122	CcSEcCtD
Tapentadol—Dyspepsia—Risedronate—osteoporosis	0.000696	0.00122	CcSEcCtD
Tapentadol—Eye disorder—Estradiol—osteoporosis	0.000696	0.00122	CcSEcCtD
Tapentadol—Constipation—Ethinyl Estradiol—osteoporosis	0.000694	0.00121	CcSEcCtD
Tapentadol—Confusional state—Zoledronate—osteoporosis	0.000693	0.00121	CcSEcCtD
Tapentadol—Hypersensitivity—Calcitriol—osteoporosis	0.000692	0.00121	CcSEcCtD
Tapentadol—Cardiac disorder—Estradiol—osteoporosis	0.000692	0.00121	CcSEcCtD
Tapentadol—Arthralgia—Conjugated Estrogens—osteoporosis	0.00069	0.0012	CcSEcCtD
Tapentadol—Asthenia—Ibandronate—osteoporosis	0.000689	0.0012	CcSEcCtD
Tapentadol—Anxiety—Conjugated Estrogens—osteoporosis	0.000688	0.0012	CcSEcCtD
Tapentadol—Nausea—Etidronic acid—osteoporosis	0.000687	0.0012	CcSEcCtD
Tapentadol—Oedema—Zoledronate—osteoporosis	0.000687	0.0012	CcSEcCtD
Tapentadol—Anaphylactic shock—Zoledronate—osteoporosis	0.000687	0.0012	CcSEcCtD
Tapentadol—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—osteoporosis	0.000685	0.0012	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Pamidronate—osteoporosis	0.000685	0.0012	CcSEcCtD
Tapentadol—Diarrhoea—Estropipate—osteoporosis	0.000685	0.0012	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Risedronate—osteoporosis	0.000683	0.00119	CcSEcCtD
Tapentadol—Infection—Zoledronate—osteoporosis	0.000682	0.00119	CcSEcCtD
Tapentadol—Fatigue—Risedronate—osteoporosis	0.000682	0.00119	CcSEcCtD
Tapentadol—Insomnia—Pamidronate—osteoporosis	0.00068	0.00119	CcSEcCtD
Tapentadol—Pruritus—Ibandronate—osteoporosis	0.000679	0.00119	CcSEcCtD
Tapentadol—Constipation—Risedronate—osteoporosis	0.000677	0.00118	CcSEcCtD
Tapentadol—Angiopathy—Estradiol—osteoporosis	0.000676	0.00118	CcSEcCtD
Tapentadol—Shock—Zoledronate—osteoporosis	0.000676	0.00118	CcSEcCtD
Tapentadol—Paraesthesia—Pamidronate—osteoporosis	0.000675	0.00118	CcSEcCtD
Tapentadol—Diarrhoea—Alendronate—osteoporosis	0.000675	0.00118	CcSEcCtD
Tapentadol—Asthenia—Calcitriol—osteoporosis	0.000674	0.00118	CcSEcCtD
Tapentadol—Nervous system disorder—Zoledronate—osteoporosis	0.000674	0.00118	CcSEcCtD
Tapentadol—Immune system disorder—Estradiol—osteoporosis	0.000673	0.00117	CcSEcCtD
Tapentadol—Mediastinal disorder—Estradiol—osteoporosis	0.000672	0.00117	CcSEcCtD
Tapentadol—Dyspnoea—Pamidronate—osteoporosis	0.00067	0.00117	CcSEcCtD
Tapentadol—Tachycardia—Zoledronate—osteoporosis	0.00067	0.00117	CcSEcCtD
Tapentadol—Feeling abnormal—Ethinyl Estradiol—osteoporosis	0.000669	0.00117	CcSEcCtD
Tapentadol—Chills—Estradiol—osteoporosis	0.000669	0.00117	CcSEcCtD
Tapentadol—Somnolence—Pamidronate—osteoporosis	0.000669	0.00117	CcSEcCtD
Tapentadol—Skin disorder—Zoledronate—osteoporosis	0.000667	0.00116	CcSEcCtD
Tapentadol—Pruritus—Calcitriol—osteoporosis	0.000665	0.00116	CcSEcCtD
Tapentadol—Hyperhidrosis—Zoledronate—osteoporosis	0.000664	0.00116	CcSEcCtD
Tapentadol—Diarrhoea—Raloxifene—osteoporosis	0.000663	0.00116	CcSEcCtD
Tapentadol—Dyspepsia—Pamidronate—osteoporosis	0.000662	0.00116	CcSEcCtD
Tapentadol—Dizziness—Estropipate—osteoporosis	0.000662	0.00116	CcSEcCtD
Tapentadol—Anaphylactic shock—Conjugated Estrogens—osteoporosis	0.000661	0.00115	CcSEcCtD
Tapentadol—Oedema—Conjugated Estrogens—osteoporosis	0.000661	0.00115	CcSEcCtD
Tapentadol—Infection—Conjugated Estrogens—osteoporosis	0.000657	0.00115	CcSEcCtD
Tapentadol—Diarrhoea—Ibandronate—osteoporosis	0.000657	0.00115	CcSEcCtD
Tapentadol—Decreased appetite—Pamidronate—osteoporosis	0.000654	0.00114	CcSEcCtD
Tapentadol—Mental disorder—Estradiol—osteoporosis	0.000653	0.00114	CcSEcCtD
Tapentadol—Dizziness—Alendronate—osteoporosis	0.000652	0.00114	CcSEcCtD
Tapentadol—Shock—Conjugated Estrogens—osteoporosis	0.000651	0.00114	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Pamidronate—osteoporosis	0.000649	0.00113	CcSEcCtD
Tapentadol—Nervous system disorder—Conjugated Estrogens—osteoporosis	0.000649	0.00113	CcSEcCtD
Tapentadol—Malnutrition—Estradiol—osteoporosis	0.000649	0.00113	CcSEcCtD
Tapentadol—Fatigue—Pamidronate—osteoporosis	0.000648	0.00113	CcSEcCtD
Tapentadol—Tachycardia—Conjugated Estrogens—osteoporosis	0.000646	0.00113	CcSEcCtD
Tapentadol—Urticaria—Ethinyl Estradiol—osteoporosis	0.000645	0.00112	CcSEcCtD
Tapentadol—Constipation—Pamidronate—osteoporosis	0.000643	0.00112	CcSEcCtD
Tapentadol—Diarrhoea—Calcitriol—osteoporosis	0.000643	0.00112	CcSEcCtD
Tapentadol—Skin disorder—Conjugated Estrogens—osteoporosis	0.000642	0.00112	CcSEcCtD
Tapentadol—Hypotension—Zoledronate—osteoporosis	0.000642	0.00112	CcSEcCtD
Tapentadol—Dizziness—Raloxifene—osteoporosis	0.000641	0.00112	CcSEcCtD
Tapentadol—Hyperhidrosis—Conjugated Estrogens—osteoporosis	0.000639	0.00112	CcSEcCtD
Tapentadol—Tension—Estradiol—osteoporosis	0.000637	0.00111	CcSEcCtD
Tapentadol—Vomiting—Estropipate—osteoporosis	0.000636	0.00111	CcSEcCtD
Tapentadol—Dizziness—Ibandronate—osteoporosis	0.000635	0.00111	CcSEcCtD
Tapentadol—Rash—Estropipate—osteoporosis	0.000631	0.0011	CcSEcCtD
Tapentadol—Dermatitis—Estropipate—osteoporosis	0.000631	0.0011	CcSEcCtD
Tapentadol—Nervousness—Estradiol—osteoporosis	0.00063	0.0011	CcSEcCtD
Tapentadol—Urticaria—Risedronate—osteoporosis	0.000628	0.0011	CcSEcCtD
Tapentadol—Headache—Estropipate—osteoporosis	0.000627	0.00109	CcSEcCtD
Tapentadol—Vomiting—Alendronate—osteoporosis	0.000627	0.00109	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Zoledronate—osteoporosis	0.000626	0.00109	CcSEcCtD
Tapentadol—Rash—Alendronate—osteoporosis	0.000622	0.00108	CcSEcCtD
Tapentadol—Insomnia—Zoledronate—osteoporosis	0.000621	0.00108	CcSEcCtD
Tapentadol—Dermatitis—Alendronate—osteoporosis	0.000621	0.00108	CcSEcCtD
Tapentadol—Feeling abnormal—Pamidronate—osteoporosis	0.00062	0.00108	CcSEcCtD
Tapentadol—Hypotension—Conjugated Estrogens—osteoporosis	0.000618	0.00108	CcSEcCtD
Tapentadol—Headache—Alendronate—osteoporosis	0.000618	0.00108	CcSEcCtD
Tapentadol—Paraesthesia—Zoledronate—osteoporosis	0.000617	0.00108	CcSEcCtD
Tapentadol—Vomiting—Raloxifene—osteoporosis	0.000617	0.00108	CcSEcCtD
Tapentadol—Dyspnoea—Zoledronate—osteoporosis	0.000612	0.00107	CcSEcCtD
Tapentadol—Rash—Raloxifene—osteoporosis	0.000611	0.00107	CcSEcCtD
Tapentadol—Dermatitis—Raloxifene—osteoporosis	0.000611	0.00107	CcSEcCtD
Tapentadol—Somnolence—Zoledronate—osteoporosis	0.000611	0.00107	CcSEcCtD
Tapentadol—Vomiting—Ibandronate—osteoporosis	0.00061	0.00106	CcSEcCtD
Tapentadol—Tremor—Estradiol—osteoporosis	0.000608	0.00106	CcSEcCtD
Tapentadol—Headache—Raloxifene—osteoporosis	0.000607	0.00106	CcSEcCtD
Tapentadol—Rash—Ibandronate—osteoporosis	0.000605	0.00106	CcSEcCtD
Tapentadol—Dermatitis—Ibandronate—osteoporosis	0.000605	0.00106	CcSEcCtD
Tapentadol—Dyspepsia—Zoledronate—osteoporosis	0.000605	0.00106	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Conjugated Estrogens—osteoporosis	0.000603	0.00105	CcSEcCtD
Tapentadol—Headache—Ibandronate—osteoporosis	0.000601	0.00105	CcSEcCtD
Tapentadol—Insomnia—Conjugated Estrogens—osteoporosis	0.000598	0.00104	CcSEcCtD
Tapentadol—Hypersensitivity—Ethinyl Estradiol—osteoporosis	0.000598	0.00104	CcSEcCtD
Tapentadol—Vomiting—Calcitriol—osteoporosis	0.000597	0.00104	CcSEcCtD
Tapentadol—Decreased appetite—Zoledronate—osteoporosis	0.000597	0.00104	CcSEcCtD
Tapentadol—Agitation—Estradiol—osteoporosis	0.000596	0.00104	CcSEcCtD
Tapentadol—Nausea—Estropipate—osteoporosis	0.000595	0.00104	CcSEcCtD
Tapentadol—Paraesthesia—Conjugated Estrogens—osteoporosis	0.000594	0.00104	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Zoledronate—osteoporosis	0.000593	0.00103	CcSEcCtD
Tapentadol—Angioedema—Estradiol—osteoporosis	0.000593	0.00103	CcSEcCtD
Tapentadol—Rash—Calcitriol—osteoporosis	0.000593	0.00103	CcSEcCtD
Tapentadol—Fatigue—Zoledronate—osteoporosis	0.000592	0.00103	CcSEcCtD
Tapentadol—Dermatitis—Calcitriol—osteoporosis	0.000592	0.00103	CcSEcCtD
Tapentadol—Dyspnoea—Conjugated Estrogens—osteoporosis	0.00059	0.00103	CcSEcCtD
Tapentadol—Headache—Calcitriol—osteoporosis	0.000589	0.00103	CcSEcCtD
Tapentadol—Somnolence—Conjugated Estrogens—osteoporosis	0.000588	0.00103	CcSEcCtD
Tapentadol—Constipation—Zoledronate—osteoporosis	0.000587	0.00103	CcSEcCtD
Tapentadol—Nausea—Alendronate—osteoporosis	0.000586	0.00102	CcSEcCtD
Tapentadol—Hypersensitivity—Risedronate—osteoporosis	0.000583	0.00102	CcSEcCtD
Tapentadol—Vertigo—Estradiol—osteoporosis	0.000583	0.00102	CcSEcCtD
Tapentadol—Dyspepsia—Conjugated Estrogens—osteoporosis	0.000582	0.00102	CcSEcCtD
Tapentadol—Asthenia—Ethinyl Estradiol—osteoporosis	0.000582	0.00102	CcSEcCtD
Tapentadol—Syncope—Estradiol—osteoporosis	0.000582	0.00101	CcSEcCtD
Tapentadol—Nausea—Raloxifene—osteoporosis	0.000576	0.00101	CcSEcCtD
Tapentadol—Decreased appetite—Conjugated Estrogens—osteoporosis	0.000575	0.001	CcSEcCtD
Tapentadol—Pruritus—Ethinyl Estradiol—osteoporosis	0.000574	0.001	CcSEcCtD
Tapentadol—Palpitations—Estradiol—osteoporosis	0.000573	0.001	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Conjugated Estrogens—osteoporosis	0.000571	0.000996	CcSEcCtD
Tapentadol—Fatigue—Conjugated Estrogens—osteoporosis	0.00057	0.000995	CcSEcCtD
Tapentadol—Nausea—Ibandronate—osteoporosis	0.00057	0.000995	CcSEcCtD
Tapentadol—Loss of consciousness—Estradiol—osteoporosis	0.00057	0.000995	CcSEcCtD
Tapentadol—Asthenia—Risedronate—osteoporosis	0.000568	0.00099	CcSEcCtD
Tapentadol—Feeling abnormal—Zoledronate—osteoporosis	0.000566	0.000988	CcSEcCtD
Tapentadol—Cough—Estradiol—osteoporosis	0.000566	0.000988	CcSEcCtD
Tapentadol—Constipation—Conjugated Estrogens—osteoporosis	0.000566	0.000987	CcSEcCtD
Tapentadol—Pruritus—Risedronate—osteoporosis	0.00056	0.000977	CcSEcCtD
Tapentadol—Nausea—Calcitriol—osteoporosis	0.000558	0.000974	CcSEcCtD
Tapentadol—Diarrhoea—Ethinyl Estradiol—osteoporosis	0.000555	0.000969	CcSEcCtD
Tapentadol—Hypersensitivity—Pamidronate—osteoporosis	0.000554	0.000967	CcSEcCtD
Tapentadol—Arthralgia—Estradiol—osteoporosis	0.000552	0.000964	CcSEcCtD
Tapentadol—Anxiety—Estradiol—osteoporosis	0.00055	0.00096	CcSEcCtD
Tapentadol—Unspecified disorder of skin and subcutaneous tissue—Estradiol—osteoporosis	0.000548	0.000957	CcSEcCtD
Tapentadol—Urticaria—Zoledronate—osteoporosis	0.000546	0.000952	CcSEcCtD
Tapentadol—Diarrhoea—Risedronate—osteoporosis	0.000541	0.000944	CcSEcCtD
Tapentadol—Dry mouth—Estradiol—osteoporosis	0.00054	0.000942	CcSEcCtD
Tapentadol—Asthenia—Pamidronate—osteoporosis	0.00054	0.000941	CcSEcCtD
Tapentadol—Dizziness—Ethinyl Estradiol—osteoporosis	0.000537	0.000936	CcSEcCtD
Tapentadol—Confusional state—Estradiol—osteoporosis	0.000534	0.000931	CcSEcCtD
Tapentadol—Pruritus—Pamidronate—osteoporosis	0.000532	0.000928	CcSEcCtD
Tapentadol—Oedema—Estradiol—osteoporosis	0.000529	0.000924	CcSEcCtD
Tapentadol—Anaphylactic shock—Estradiol—osteoporosis	0.000529	0.000924	CcSEcCtD
Tapentadol—Infection—Estradiol—osteoporosis	0.000526	0.000918	CcSEcCtD
Tapentadol—Urticaria—Conjugated Estrogens—osteoporosis	0.000525	0.000917	CcSEcCtD
Tapentadol—Dizziness—Risedronate—osteoporosis	0.000523	0.000913	CcSEcCtD
Tapentadol—Shock—Estradiol—osteoporosis	0.000521	0.000909	CcSEcCtD
Tapentadol—Nervous system disorder—Estradiol—osteoporosis	0.000519	0.000906	CcSEcCtD
Tapentadol—Tachycardia—Estradiol—osteoporosis	0.000517	0.000902	CcSEcCtD
Tapentadol—Vomiting—Ethinyl Estradiol—osteoporosis	0.000516	0.0009	CcSEcCtD
Tapentadol—Diarrhoea—Pamidronate—osteoporosis	0.000515	0.000898	CcSEcCtD
Tapentadol—Skin disorder—Estradiol—osteoporosis	0.000514	0.000897	CcSEcCtD
Tapentadol—Hyperhidrosis—Estradiol—osteoporosis	0.000512	0.000893	CcSEcCtD
Tapentadol—Rash—Ethinyl Estradiol—osteoporosis	0.000512	0.000893	CcSEcCtD
Tapentadol—Dermatitis—Ethinyl Estradiol—osteoporosis	0.000511	0.000892	CcSEcCtD
Tapentadol—Headache—Ethinyl Estradiol—osteoporosis	0.000508	0.000887	CcSEcCtD
Tapentadol—Hypersensitivity—Zoledronate—osteoporosis	0.000506	0.000883	CcSEcCtD
Tapentadol—Vomiting—Risedronate—osteoporosis	0.000503	0.000878	CcSEcCtD
Tapentadol—Rash—Risedronate—osteoporosis	0.000499	0.00087	CcSEcCtD
Tapentadol—Dermatitis—Risedronate—osteoporosis	0.000498	0.00087	CcSEcCtD
Tapentadol—Dizziness—Pamidronate—osteoporosis	0.000497	0.000868	CcSEcCtD
Tapentadol—Headache—Risedronate—osteoporosis	0.000496	0.000865	CcSEcCtD
Tapentadol—Asthenia—Zoledronate—osteoporosis	0.000493	0.00086	CcSEcCtD
Tapentadol—Hypersensitivity—Conjugated Estrogens—osteoporosis	0.000487	0.00085	CcSEcCtD
Tapentadol—Pruritus—Zoledronate—osteoporosis	0.000486	0.000848	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Estradiol—osteoporosis	0.000482	0.000842	CcSEcCtD
Tapentadol—Nausea—Ethinyl Estradiol—osteoporosis	0.000482	0.000841	CcSEcCtD
Tapentadol—Insomnia—Estradiol—osteoporosis	0.000479	0.000835	CcSEcCtD
Tapentadol—Vomiting—Pamidronate—osteoporosis	0.000478	0.000834	CcSEcCtD
Tapentadol—Paraesthesia—Estradiol—osteoporosis	0.000475	0.000829	CcSEcCtD
Tapentadol—Asthenia—Conjugated Estrogens—osteoporosis	0.000475	0.000828	CcSEcCtD
Tapentadol—Rash—Pamidronate—osteoporosis	0.000474	0.000827	CcSEcCtD
Tapentadol—Dermatitis—Pamidronate—osteoporosis	0.000474	0.000827	CcSEcCtD
Tapentadol—Dyspnoea—Estradiol—osteoporosis	0.000472	0.000824	CcSEcCtD
Tapentadol—Headache—Pamidronate—osteoporosis	0.000471	0.000822	CcSEcCtD
Tapentadol—Somnolence—Estradiol—osteoporosis	0.000471	0.000821	CcSEcCtD
Tapentadol—Diarrhoea—Zoledronate—osteoporosis	0.00047	0.00082	CcSEcCtD
Tapentadol—Nausea—Risedronate—osteoporosis	0.00047	0.00082	CcSEcCtD
Tapentadol—Pruritus—Conjugated Estrogens—osteoporosis	0.000468	0.000817	CcSEcCtD
Tapentadol—Dyspepsia—Estradiol—osteoporosis	0.000466	0.000813	CcSEcCtD
Tapentadol—Decreased appetite—Estradiol—osteoporosis	0.00046	0.000803	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Estradiol—osteoporosis	0.000457	0.000797	CcSEcCtD
Tapentadol—Fatigue—Estradiol—osteoporosis	0.000456	0.000796	CcSEcCtD
Tapentadol—Dizziness—Zoledronate—osteoporosis	0.000454	0.000793	CcSEcCtD
Tapentadol—Constipation—Estradiol—osteoporosis	0.000453	0.00079	CcSEcCtD
Tapentadol—Diarrhoea—Conjugated Estrogens—osteoporosis	0.000453	0.00079	CcSEcCtD
Tapentadol—Nausea—Pamidronate—osteoporosis	0.000447	0.000779	CcSEcCtD
Tapentadol—Dizziness—Conjugated Estrogens—osteoporosis	0.000437	0.000763	CcSEcCtD
Tapentadol—Vomiting—Zoledronate—osteoporosis	0.000437	0.000762	CcSEcCtD
Tapentadol—Feeling abnormal—Estradiol—osteoporosis	0.000436	0.000761	CcSEcCtD
Tapentadol—Rash—Zoledronate—osteoporosis	0.000433	0.000756	CcSEcCtD
Tapentadol—Dermatitis—Zoledronate—osteoporosis	0.000433	0.000755	CcSEcCtD
Tapentadol—Headache—Zoledronate—osteoporosis	0.00043	0.000751	CcSEcCtD
Tapentadol—Vomiting—Conjugated Estrogens—osteoporosis	0.000421	0.000734	CcSEcCtD
Tapentadol—Urticaria—Estradiol—osteoporosis	0.000421	0.000734	CcSEcCtD
Tapentadol—Rash—Conjugated Estrogens—osteoporosis	0.000417	0.000728	CcSEcCtD
Tapentadol—Dermatitis—Conjugated Estrogens—osteoporosis	0.000417	0.000727	CcSEcCtD
Tapentadol—Headache—Conjugated Estrogens—osteoporosis	0.000414	0.000723	CcSEcCtD
Tapentadol—Nausea—Zoledronate—osteoporosis	0.000408	0.000712	CcSEcCtD
Tapentadol—Nausea—Conjugated Estrogens—osteoporosis	0.000393	0.000686	CcSEcCtD
Tapentadol—Hypersensitivity—Estradiol—osteoporosis	0.00039	0.000681	CcSEcCtD
Tapentadol—Asthenia—Estradiol—osteoporosis	0.00038	0.000663	CcSEcCtD
Tapentadol—Pruritus—Estradiol—osteoporosis	0.000375	0.000654	CcSEcCtD
Tapentadol—Diarrhoea—Estradiol—osteoporosis	0.000362	0.000632	CcSEcCtD
Tapentadol—Dizziness—Estradiol—osteoporosis	0.00035	0.000611	CcSEcCtD
Tapentadol—Vomiting—Estradiol—osteoporosis	0.000337	0.000587	CcSEcCtD
Tapentadol—Rash—Estradiol—osteoporosis	0.000334	0.000582	CcSEcCtD
Tapentadol—Dermatitis—Estradiol—osteoporosis	0.000333	0.000582	CcSEcCtD
Tapentadol—Headache—Estradiol—osteoporosis	0.000332	0.000579	CcSEcCtD
Tapentadol—Nausea—Estradiol—osteoporosis	0.000314	0.000549	CcSEcCtD
Tapentadol—OPRK1—Signaling by GPCR—WNT1—osteoporosis	8.27e-05	0.00144	CbGpPWpGaD
Tapentadol—OPRD1—GPCR downstream signaling—CALCA—osteoporosis	8.27e-05	0.00144	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—PTHLH—osteoporosis	8.24e-05	0.00144	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—OXCT1—osteoporosis	8.23e-05	0.00144	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—CYP27A1—osteoporosis	8.2e-05	0.00143	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—CNR2—osteoporosis	8.19e-05	0.00143	CbGpPWpGaD
Tapentadol—UGT1A9—NRF2 pathway—TGFB1—osteoporosis	8.09e-05	0.00141	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—MGLL—osteoporosis	8.06e-05	0.00141	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—MGLL—osteoporosis	8.02e-05	0.0014	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—ACP5—osteoporosis	7.98e-05	0.00139	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—LRP5—osteoporosis	7.87e-05	0.00137	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	7.86e-05	0.00137	CbGpPWpGaD
Tapentadol—OPRD1—GPCR ligand binding—POMC—osteoporosis	7.66e-05	0.00134	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—PTH—osteoporosis	7.63e-05	0.00133	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—LRP6—osteoporosis	7.53e-05	0.00131	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—CALCA—osteoporosis	7.51e-05	0.00131	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—PTHLH—osteoporosis	7.48e-05	0.00131	CbGpPWpGaD
Tapentadol—OPRM1—Class A/1 (Rhodopsin-like receptors)—POMC—osteoporosis	7.45e-05	0.0013	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—CNR2—osteoporosis	7.43e-05	0.0013	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—TPI1—osteoporosis	7.42e-05	0.00129	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—CALCA—osteoporosis	7.25e-05	0.00127	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—TLN1—osteoporosis	7.25e-05	0.00127	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—IDH2—osteoporosis	7.09e-05	0.00124	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—CYP27A1—osteoporosis	7.03e-05	0.00123	CbGpPWpGaD
Tapentadol—SLC6A4—SIDS Susceptibility Pathways—IL6—osteoporosis	7e-05	0.00122	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—WNT1—osteoporosis	6.99e-05	0.00122	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—P4HB—osteoporosis	6.97e-05	0.00122	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—PTHLH—osteoporosis	6.96e-05	0.00122	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—GAPDH—osteoporosis	6.84e-05	0.0012	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—MGLL—osteoporosis	6.82e-05	0.00119	CbGpPWpGaD
Tapentadol—OPRK1—GPCR ligand binding—POMC—osteoporosis	6.71e-05	0.00117	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—RAP1A—osteoporosis	6.67e-05	0.00116	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—CYP27A1—osteoporosis	6.66e-05	0.00116	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—LRP5—osteoporosis	6.65e-05	0.00116	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—CALCA—osteoporosis	6.59e-05	0.00115	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—ACP5—osteoporosis	6.48e-05	0.00113	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—CYP27A1—osteoporosis	6.41e-05	0.00112	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	6.4e-05	0.00112	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—LRP6—osteoporosis	6.36e-05	0.00111	CbGpPWpGaD
Tapentadol—SLC6A2—Transmembrane transport of small molecules—ADCY5—osteoporosis	6.36e-05	0.00111	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—TLN1—osteoporosis	6.36e-05	0.00111	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—PTHLH—osteoporosis	6.32e-05	0.0011	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—P4HB—osteoporosis	6.25e-05	0.00109	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—CALCA—osteoporosis	6.13e-05	0.00107	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—PTH—osteoporosis	6.08e-05	0.00106	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—TPI1—osteoporosis	6.03e-05	0.00105	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—P4HB—osteoporosis	5.98e-05	0.00104	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—RAP1A—osteoporosis	5.98e-05	0.00104	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—CNR2—osteoporosis	5.93e-05	0.00103	CbGpPWpGaD
Tapentadol—OPRD1—GPCR downstream signaling—ADCY5—osteoporosis	5.88e-05	0.00103	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—NFATC1—osteoporosis	5.83e-05	0.00102	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—DKK1—osteoporosis	5.78e-05	0.00101	CbGpPWpGaD
Tapentadol—CYP2C19—Biological oxidations—POMC—osteoporosis	5.78e-05	0.00101	CbGpPWpGaD
Tapentadol—SLC6A4—Circadian rythm related genes—IL6—osteoporosis	5.72e-05	0.000998	CbGpPWpGaD
Tapentadol—OPRM1—GPCR ligand binding—POMC—osteoporosis	5.67e-05	0.000991	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—P4HB—osteoporosis	5.67e-05	0.000989	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—WNT1—osteoporosis	5.57e-05	0.000973	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—CALCA—osteoporosis	5.57e-05	0.000972	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—GAPDH—osteoporosis	5.56e-05	0.000971	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—P4HB—osteoporosis	5.48e-05	0.000957	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PKM—osteoporosis	5.45e-05	0.000952	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—FDPS—osteoporosis	5.45e-05	0.000952	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—P4HB—osteoporosis	5.45e-05	0.000952	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—FGA—osteoporosis	5.42e-05	0.000946	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—RAP1A—osteoporosis	5.42e-05	0.000946	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—ENO1—osteoporosis	5.39e-05	0.000941	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—TLN1—osteoporosis	5.37e-05	0.000938	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—ADCY5—osteoporosis	5.34e-05	0.000933	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—PTH—osteoporosis	5.33e-05	0.000931	CbGpPWpGaD
Tapentadol—CYP2D6—Biological oxidations—POMC—osteoporosis	5.32e-05	0.000928	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—PSMA2—osteoporosis	5.31e-05	0.000927	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—PSMA5—osteoporosis	5.31e-05	0.000927	CbGpPWpGaD
Tapentadol—CYP2C9—Biological oxidations—POMC—osteoporosis	5.27e-05	0.00092	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—RAP1A—osteoporosis	5.24e-05	0.000915	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CNR2—osteoporosis	5.2e-05	0.000907	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—GPD2—osteoporosis	5.17e-05	0.000903	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PGLS—osteoporosis	5.17e-05	0.000903	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—ADCY5—osteoporosis	5.16e-05	0.000901	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—NFATC1—osteoporosis	5.11e-05	0.000893	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—DKK1—osteoporosis	5.07e-05	0.000886	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—PTHLH—osteoporosis	5.04e-05	0.00088	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—BMP2—osteoporosis	5.04e-05	0.00088	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PKM—osteoporosis	5.02e-05	0.000876	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—FDPS—osteoporosis	5.02e-05	0.000876	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PKM—osteoporosis	4.97e-05	0.000868	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—FDPS—osteoporosis	4.97e-05	0.000868	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—FGB—osteoporosis	4.93e-05	0.000861	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—WNT1—osteoporosis	4.89e-05	0.000853	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—PSMA2—osteoporosis	4.76e-05	0.000831	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—PSMA5—osteoporosis	4.76e-05	0.000831	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PGLS—osteoporosis	4.75e-05	0.00083	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—GPD2—osteoporosis	4.75e-05	0.00083	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—FGA—osteoporosis	4.75e-05	0.00083	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PNP—osteoporosis	4.73e-05	0.000826	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—ATIC—osteoporosis	4.73e-05	0.000826	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism of lipids and lipoproteins—POMC—osteoporosis	4.72e-05	0.000825	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PGLS—osteoporosis	4.71e-05	0.000823	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—GPD2—osteoporosis	4.71e-05	0.000823	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—ADCY5—osteoporosis	4.68e-05	0.000818	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—P4HB—osteoporosis	4.63e-05	0.000809	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—PTH—osteoporosis	4.51e-05	0.000787	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—CALCA—osteoporosis	4.44e-05	0.000775	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—RAP1A—osteoporosis	4.43e-05	0.000773	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—PTHLH—osteoporosis	4.42e-05	0.000771	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—BMP2—osteoporosis	4.42e-05	0.000771	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CNR2—osteoporosis	4.39e-05	0.000767	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—ENO1—osteoporosis	4.38e-05	0.000765	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—ADCY5—osteoporosis	4.36e-05	0.000761	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—ATIC—osteoporosis	4.35e-05	0.000759	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PNP—osteoporosis	4.35e-05	0.000759	CbGpPWpGaD
Tapentadol—OPRD1—GPCR downstream signaling—POMC—osteoporosis	4.33e-05	0.000755	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—FGB—osteoporosis	4.32e-05	0.000755	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—NFATC1—osteoporosis	4.32e-05	0.000754	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—PSMA2—osteoporosis	4.31e-05	0.000753	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—PSMA5—osteoporosis	4.31e-05	0.000753	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—ATIC—osteoporosis	4.31e-05	0.000753	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PNP—osteoporosis	4.31e-05	0.000753	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—CYP19A1—osteoporosis	4.31e-05	0.000752	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—DKK1—osteoporosis	4.29e-05	0.000748	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—PSMA2—osteoporosis	4.17e-05	0.000729	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—PSMA5—osteoporosis	4.17e-05	0.000729	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—WNT1—osteoporosis	4.13e-05	0.000721	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—KL—osteoporosis	4.03e-05	0.000703	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—CA2—osteoporosis	4.02e-05	0.000702	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—OXCT1—osteoporosis	4.02e-05	0.000702	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—FGA—osteoporosis	4.02e-05	0.000701	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—ADCY5—osteoporosis	3.96e-05	0.000691	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—POMC—osteoporosis	3.93e-05	0.000686	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—MGLL—osteoporosis	3.92e-05	0.000684	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CALCA—osteoporosis	3.89e-05	0.000679	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—IL6R—osteoporosis	3.83e-05	0.000669	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—POMC—osteoporosis	3.79e-05	0.000662	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—PTHLH—osteoporosis	3.73e-05	0.000652	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—BMP2—osteoporosis	3.73e-05	0.000652	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—OXCT1—osteoporosis	3.7e-05	0.000646	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—CA2—osteoporosis	3.7e-05	0.000646	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	3.69e-05	0.000645	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—OXCT1—osteoporosis	3.67e-05	0.00064	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—CA2—osteoporosis	3.67e-05	0.00064	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—FGB—osteoporosis	3.65e-05	0.000638	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—MGLL—osteoporosis	3.6e-05	0.000629	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—MGLL—osteoporosis	3.57e-05	0.000624	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—KL—osteoporosis	3.53e-05	0.000617	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—PSMA2—osteoporosis	3.53e-05	0.000616	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—PSMA5—osteoporosis	3.53e-05	0.000616	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—ADCY5—osteoporosis	3.52e-05	0.000615	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—GPX1—osteoporosis	3.51e-05	0.000612	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—CYP19A1—osteoporosis	3.5e-05	0.000611	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—POMC—osteoporosis	3.45e-05	0.000602	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	3.37e-05	0.000588	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—IL6R—osteoporosis	3.36e-05	0.000587	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—IDH2—osteoporosis	3.33e-05	0.000582	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CALCA—osteoporosis	3.29e-05	0.000574	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—MTHFR—osteoporosis	3.24e-05	0.000565	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—POMC—osteoporosis	3.21e-05	0.00056	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—ADCY5—osteoporosis	3.16e-05	0.000551	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—CYP27A1—osteoporosis	3.13e-05	0.000547	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—IDH2—osteoporosis	3.06e-05	0.000535	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—SPP1—osteoporosis	3.05e-05	0.000533	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—ACP5—osteoporosis	3.05e-05	0.000532	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—IDH2—osteoporosis	3.04e-05	0.00053	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	3.01e-05	0.000525	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—KL—osteoporosis	2.99e-05	0.000521	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—POMC—osteoporosis	2.91e-05	0.000508	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—CYP27A1—osteoporosis	2.88e-05	0.000503	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—ADCY5—osteoporosis	2.86e-05	0.000499	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—CYP27A1—osteoporosis	2.86e-05	0.000499	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—GPX1—osteoporosis	2.85e-05	0.000498	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—IL6R—osteoporosis	2.84e-05	0.000496	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—TPI1—osteoporosis	2.83e-05	0.000495	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—ACP5—osteoporosis	2.8e-05	0.000489	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—ACP5—osteoporosis	2.78e-05	0.000485	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—ADCY5—osteoporosis	2.77e-05	0.000483	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—IRS2—osteoporosis	2.76e-05	0.000482	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	2.74e-05	0.000479	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—LEP—osteoporosis	2.7e-05	0.000472	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—SPP1—osteoporosis	2.68e-05	0.000467	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—P4HB—osteoporosis	2.66e-05	0.000465	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—MTHFR—osteoporosis	2.63e-05	0.000459	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—GAPDH—osteoporosis	2.61e-05	0.000456	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—TPI1—osteoporosis	2.61e-05	0.000455	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—POMC—osteoporosis	2.59e-05	0.000452	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—TPI1—osteoporosis	2.58e-05	0.000451	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—ESR1—osteoporosis	2.58e-05	0.00045	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—RAP1A—osteoporosis	2.55e-05	0.000445	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—P4HB—osteoporosis	2.45e-05	0.000428	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—P4HB—osteoporosis	2.43e-05	0.000424	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—IRS2—osteoporosis	2.42e-05	0.000423	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—IRS1—osteoporosis	2.41e-05	0.000421	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—GAPDH—osteoporosis	2.4e-05	0.00042	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—GAPDH—osteoporosis	2.38e-05	0.000416	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—LEP—osteoporosis	2.37e-05	0.000414	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—RAP1A—osteoporosis	2.34e-05	0.000409	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—ADCY5—osteoporosis	2.34e-05	0.000408	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—RAP1A—osteoporosis	2.32e-05	0.000405	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—POMC—osteoporosis	2.32e-05	0.000405	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—IL6R—osteoporosis	2.26e-05	0.000395	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—SPP1—osteoporosis	2.26e-05	0.000395	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—ESR1—osteoporosis	2.26e-05	0.000395	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—IGF1—osteoporosis	2.23e-05	0.00039	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—POMC—osteoporosis	2.22e-05	0.000388	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—IRS1—osteoporosis	2.11e-05	0.000369	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—POMC—osteoporosis	2.1e-05	0.000367	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—ENO1—osteoporosis	2.06e-05	0.000359	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—IRS2—osteoporosis	2.05e-05	0.000357	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—POMC—osteoporosis	2.04e-05	0.000355	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PSMA2—osteoporosis	2.03e-05	0.000354	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PSMA5—osteoporosis	2.03e-05	0.000354	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—POMC—osteoporosis	2.02e-05	0.000353	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—LEP—osteoporosis	2e-05	0.00035	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—IL6R—osteoporosis	1.99e-05	0.000347	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—IGF1—osteoporosis	1.96e-05	0.000342	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—ESR1—osteoporosis	1.91e-05	0.000334	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—ENO1—osteoporosis	1.89e-05	0.00033	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—ENO1—osteoporosis	1.88e-05	0.000328	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PSMA2—osteoporosis	1.87e-05	0.000326	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PSMA5—osteoporosis	1.87e-05	0.000326	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PSMA2—osteoporosis	1.85e-05	0.000323	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PSMA5—osteoporosis	1.85e-05	0.000323	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—IRS1—osteoporosis	1.79e-05	0.000312	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—POMC—osteoporosis	1.72e-05	0.0003	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—IL6—osteoporosis	1.71e-05	0.000298	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—IL6R—osteoporosis	1.68e-05	0.000293	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—IGF1—osteoporosis	1.65e-05	0.000289	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—CYP19A1—osteoporosis	1.65e-05	0.000287	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—CYP19A1—osteoporosis	1.51e-05	0.000264	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—CYP19A1—osteoporosis	1.5e-05	0.000262	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—IL6—osteoporosis	1.5e-05	0.000261	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—ADCY5—osteoporosis	1.34e-05	0.000235	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—MYC—osteoporosis	1.34e-05	0.000234	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—GPX1—osteoporosis	1.34e-05	0.000234	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—TGFB1—osteoporosis	1.34e-05	0.000234	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—IL6—osteoporosis	1.27e-05	0.000221	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—ADCY5—osteoporosis	1.24e-05	0.000216	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—MTHFR—osteoporosis	1.24e-05	0.000216	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—GPX1—osteoporosis	1.23e-05	0.000215	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—ADCY5—osteoporosis	1.23e-05	0.000214	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—GPX1—osteoporosis	1.22e-05	0.000213	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—MYC—osteoporosis	1.18e-05	0.000205	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—TGFB1—osteoporosis	1.17e-05	0.000205	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—MTHFR—osteoporosis	1.14e-05	0.000199	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—MTHFR—osteoporosis	1.13e-05	0.000197	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—IL6—osteoporosis	1.01e-05	0.000176	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—MYC—osteoporosis	9.94e-06	0.000174	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—TGFB1—osteoporosis	9.92e-06	0.000173	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—POMC—osteoporosis	9.89e-06	0.000173	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—POMC—osteoporosis	9.09e-06	0.000159	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—POMC—osteoporosis	9.02e-06	0.000157	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—IL6—osteoporosis	8.84e-06	0.000154	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—IL6—osteoporosis	7.47e-06	0.000131	CbGpPWpGaD
